Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» Sumitomo Dainippon
Sumitomo Dainippon
In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal
In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal
Endpoints
Sumitomo Dainippon
diabetes
clinical trials
imeglimin
Poxel
Flag link:
Japanese pharma snaps up cancer biotech Tolero
Japanese pharma snaps up cancer biotech Tolero
BioPharma Dive
Japan
Tolero Pharmaceuticals
M&A
Sumitomo Dainippon
Flag link:
Looking ahead at orphan drugs' future: More breakthroughs, exploding sales
Looking ahead at orphan drugs' future: More breakthroughs, exploding sales
BioPharma Dive
orphan drugs
Sumitomo Dainippon
obeticholic acid
AbbVie
venetoclax
Actelion
Uptravi
Flag link:
Intercept's much-hyped NASH drug misses the mark in Phase II
Intercept's much-hyped NASH drug misses the mark in Phase II
Fierce Biotech
Intercept Pharmaceuticals
NASH
Sumitomo Dainippon
Japan
OCA
Flag link:
